National Grid announces scrip dividend reference price for 2025/26

Investing.comThursday, November 27, 2025 at 4:32:25 PM
National Grid announces scrip dividend reference price for 2025/26
  • National Grid has announced the scrip dividend reference price for the fiscal year 2025/26, a move that provides shareholders with an option to receive dividends in the form of additional shares instead of cash. This announcement is part of the company's ongoing strategy to enhance shareholder value and maintain investor confidence.
  • The scrip dividend option allows shareholders to reinvest their dividends, potentially increasing their stake in the company without incurring additional costs. This approach can be particularly appealing in a fluctuating market environment, where cash flow management is crucial.
  • The announcement comes amid mixed signals in the broader energy market, including fluctuations in natural gas storage levels and recent financial maneuvers by other companies. These developments reflect the complexities of the energy sector, where companies are navigating both operational challenges and opportunities for growth.
— via World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended apps based on your readingExplore all apps
Continue Readings
Desale Pravin, SVP at Lattice Semi, sells $399k in shares
NeutralFinancial Markets
Desale Pravin, Senior Vice President at Lattice Semiconductor, has sold $399,000 worth of shares in the company, a transaction reported by Investing.com. This sale reflects Pravin's financial decisions regarding his stake in Lattice Semi, a key player in the semiconductor industry.
Bellevue Gold stock upgraded by JPMorgan as operational turnaround nears
PositiveFinancial Markets
Bellevue Gold's stock has been upgraded by JPMorgan, signaling a positive outlook as the company approaches a significant operational turnaround. This upgrade reflects confidence in Bellevue Gold's ability to enhance its performance in the competitive gold market.
Oil edges down as investors assess oversupply, geopolitics
NeutralFinancial Markets
Oil prices have edged down as investors assess the ongoing oversupply in the market and geopolitical tensions affecting global trade. Recent reports indicate that crude oil inventories are surging, contributing to a bearish outlook for prices in the near future.
Brown Forman stock price target maintained at $30 by RBC Capital
NeutralFinancial Markets
RBC Capital has maintained its stock price target for Brown Forman at $30, indicating a stable outlook for the company amid fluctuating market conditions. This decision reflects RBC's confidence in Brown Forman's business model and market position.
McBrayer Brett buys Ampco Pittsburgh (AP) shares worth $48,944
NeutralFinancial Markets
McBrayer Brett has acquired shares of Ampco Pittsburgh valued at $48,944, as reported by Investing.com. This transaction highlights McBrayer's investment strategy and confidence in the company's future prospects.
Piper Sandler maintains Overweight rating on Chewy stock amid profitability debate
NeutralFinancial Markets
Piper Sandler has reaffirmed its Overweight rating on Chewy stock amidst ongoing discussions regarding the company's profitability. This decision reflects the investment firm's confidence in Chewy's potential for growth despite current market uncertainties.
Bank of England sees greater financial risks from AI and lending
NegativeFinancial Markets
The Bank of England has raised concerns about increasing financial risks stemming from artificial intelligence (AI) and lending practices, highlighting the potential for instability in the financial system. This warning comes amid a backdrop of significant debt-fueled investments in AI infrastructure, which the central bank believes could lead to adverse market conditions.
Harrington sells Cytokinetics (CYTK) stock worth $143,620
NeutralFinancial Markets
Harrington has sold shares of Cytokinetics (CYTK) stock valued at $143,620, a transaction reported by Investing.com. This sale reflects Harrington's financial decisions regarding his investment in the biopharmaceutical company, which focuses on developing treatments for debilitating diseases.